However, in other cancers (such as astrocytomas, oligodendrogliomas, melanomas, pulmonary endocrine tumors, and breast cancer) CA II upregulation is associated with poor prognosis, tumor progression, and metastasis [146,149,150,151]. Here, CA2 is linked to breast carcinoma.